Cagrilintide

Product Description Cagrilintide is a synthetic, long-acting acylated peptide analogue of amylin (also known as a dual amylin-calcitonin receptor agonist or DACRA). Supplied as ≥98% pure lyophilized powder (HPLC/MS verified), it is designed for laboratory studies on appetite regulation, energy balance, and metabolic disorders.

Key Research Mechanism Cagrilintide selectively activates amylin receptors (AMY1R, AMY3R) and calcitonin receptors in the brain and periphery. This promotes satiety signaling, reduces food intake, slows gastric emptying, and supports body weight reduction while preserving lean mass in research models.

Primary Research Areas

• Metabolic health & obesity models (significant weight loss and reduced adiposity in preclinical and clinical studies)
• Appetite regulation and satiety signaling via central nervous system pathways
• Gastric emptying and postprandial glucose control
• Combination therapies with GLP-1 receptor agonists for enhanced metabolic effects

Intended Use For in vitro and in vivo research only. Not for human or veterinary use. This product is sold strictly for scientific and laboratory investigation. Researchers must follow all institutional and regulatory guidelines. Not evaluated by the FDA.